Research
Omalizumab Linked With Anaphylaxis Elimination in Meat Allergy
The Brief
- In one case series, omalizumab (Xolair) appeared to eliminate anaphylaxis risk in patients with alpha-gal syndrome who still had severe allergic reactions to red meat despite avoiding it.
- The finding comes from a case series reported in MedPage Today's coverage of an ACAAI meeting, not from a controlled trial.
Why it matters
Alpha-gal syndrome is a meat allergy linked to tick bites, and patients who cannot control reactions by avoidance have few options. If confirmed, omalizumab could be a treatment option for these patients, but the evidence so far comes from a case series.
Who’s affected
- clinicians and allergists treating alpha-gal syndrome
- patients with alpha-gal syndrome who have severe reactions despite avoiding red meat
- #allergy
- #alpha-gal
- #omalizumab
- #anaphylaxis
- #meat-allergy
(MedPage Today) -- For patients with alpha-gal syndrome who had severe allergic reactions to red meat despite avoidance, treatment with omalizumab (Xolair) appeared to eliminate anaphylaxis risk in one case series. Whereas 53% of 64 such patients...